Literature DB >> 9645216

[Oral sucralfate administration for therapy and prevention of radiation-induced esophagitis: results of a placebo-controlled double-blind study].

C Belka.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9645216     DOI: 10.1007/bf03038549

Source DB:  PubMed          Journal:  Strahlenther Onkol        ISSN: 0179-7158            Impact factor:   3.621


× No keyword cloud information.
  5 in total

Review 1.  [The use of sucralfate in radiation oncology].

Authors:  C Belka; W Hoffmann; F Paulsen; M Barnberg
Journal:  Strahlenther Onkol       Date:  1997-05       Impact factor: 3.621

2.  Placebo-controlled trial of sucralfate for inhibiting radiation-induced esophagitis.

Authors:  W L McGinnis; C L Loprinzi; S J Buskirk; J A Sloan; R G Drummond; A R Frank; T G Shanahan; S P Kahanic; R L Moore; S E Schild; S L Humphrey
Journal:  J Clin Oncol       Date:  1997-03       Impact factor: 44.544

3.  Sucralfate for radiation mucositis: results of a double-blind randomized trial.

Authors:  R Meredith; M Salter; R Kim; S Spencer; B Weppelmann; B Rodu; J Smith; J Lee
Journal:  Int J Radiat Oncol Biol Phys       Date:  1997-01-15       Impact factor: 7.038

4.  Assessment of sucralfate coating by sequential scintigraphic imaging in radiation-induced esophageal lesions.

Authors:  B G Taal; R A Vales Olmos; H Boot; C A Hoefnagel
Journal:  Gastrointest Endosc       Date:  1995-02       Impact factor: 9.427

5.  Oral sucralfate in acute radiation oesophagitis.

Authors:  R K Sur; R Kochhar; D P Singh
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

  5 in total
  1 in total

1.  Radiation-induced oesophagitis in lung cancer patients. Is susceptibility for neutropenia a risk factor?

Authors:  D De Ruysscher; J Van Meerbeeck; K Vandecasteele; C Oberije; M Pijls; A M C Dingemans; B Reymen; A van Baardwijk; R Wanders; G Lammering; P Lambin; W De Neve
Journal:  Strahlenther Onkol       Date:  2012-04-29       Impact factor: 3.621

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.